Paper22004366
Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: a meta-analysis.
Li L and 5 others. J Gastroenterol Hepatol, 2012. Cited by 105 papers, by iCite.
Cite this record
ConductScience Library. Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: a meta-analysis. Papers, record 22004366. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22004366
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: a meta-analysis.
- PubMed
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Hepatocellular | Major topic |
| Catheter Ablation | Major topic |
| Hepatectomy | Major topic |
| Liver Neoplasms | Major topic |
| Adult | |
| Aged | |
| Chi-Square Distribution | |
| Disease-Free Survival | |
| Evidence-Based Medicine | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Neoplasm Recurrence, Local | |
| Odds Ratio | |
| Risk Assessment | |
| Risk Factors | |
| Survival Analysis | |
| Time Factors | |
| Treatment Outcome |
Source PubMed
Cited by62
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 105 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41993155 | Survival Outcomes, Recurrence Patterns, and Its Corresponding Therapeutic Management after Conversion Therapy Followed by Curative Resection for Hepatocellular Carcinoma: A Real-World Study. | Liver Cancer | 2026 | https://conductscience.org/library/papers/41993155 | PubMed |
| 41706888 | Oncogenic function and transcriptional dynamics of MYCN in liver tumorigenesis. | Proc Natl Acad Sci U S A | 2026 | https://conductscience.org/library/papers/41706888 | PubMed |
| 41549287 | Comparison of surgical resection and radiofrequency ablation for the treatment of small hepatocellular carcinoma (≤ 3 cm): an updated meta-analysis. | Syst Rev | 2026 | https://conductscience.org/library/papers/41549287 | PubMed |
| 41487558 | Prognostic Role of Mitotic Index in Hepatocellular Carcinoma: Potential Clinical Implications for Very Early Stage Disease. | J Hepatocell Carcinoma | 2025 | https://conductscience.org/library/papers/41487558 | PubMed |
| 41424863 | Verteporfin-loaded hydrogel targeting YAP-mediated MDSCs recruitment for the treatment of residual tumors after incomplete radiofrequency ablation. | Theranostics | 2026 | https://conductscience.org/library/papers/41424863 | PubMed |
| 41216284 | Margins matter: raising the bar for thermal ablation through quantitative imaging validation in COVER-ALL. | Transl Gastroenterol Hepatol | 2025 | https://conductscience.org/library/papers/41216284 | PubMed |
| 41063733 | China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition). | Liver Cancer | 2025 | https://conductscience.org/library/papers/41063733 | PubMed |
| 40946121 | Comparative Efficacy of Thermal Ablation and Surgical Resection in Patients with Colorectal Cancer Liver Metastasis: A Systematic Review and Meta-analysis. | J Gastrointest Cancer | 2025 | https://conductscience.org/library/papers/40946121 | PubMed |
| 40702937 | Real-world treatment patterns and outcomes in patients with early-stage HCC in the US treated with resection or ablation. | Hepat Oncol | 2025 | https://conductscience.org/library/papers/40702937 | PubMed |
| 40547962 | Chinese Expert Consensus on the Combination of Targeted Therapy and Immunotherapy with Locoregional Therapy for Intermediate/Advanced Hepatocellular Carcinoma. | Liver Cancer | 2025 | https://conductscience.org/library/papers/40547962 | PubMed |
| 40201353 | Lenvatinib-induced pemphigus erythematosus in hepatocellular carcinoma: a unique case report. | Front Oncol | 2025 | https://conductscience.org/library/papers/40201353 | PubMed |
| 40144682 | Future perspectives on immunotherapy for hepatocellular carcinoma. | Ther Adv Med Oncol | 2025 | https://conductscience.org/library/papers/40144682 | PubMed |
| 39881557 | Comparison of long-term clinical outcomes between radiofrequency ablation and hepatic resection in patients with small (≤2 cm) hepatocellular carcinoma. | Hepat Oncol | 2024 | https://conductscience.org/library/papers/39881557 | PubMed |
| 39687037 | Challenges in Adjuvant Immunotherapy after Resection or Ablation for Hepatocellular Carcinoma at High-Risk of Recurrence. | Liver Cancer | 2024 | https://conductscience.org/library/papers/39687037 | PubMed |
| 39570557 | APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024. | Hepatol Int | 2024 | https://conductscience.org/library/papers/39570557 | PubMed |
| 38854817 | Prolonged Complete Remission Using Tislelizumab for Hepatocellular Carcinoma After Adjuvant Chemotherapy Failure: A Case Report. | J Hepatocell Carcinoma | 2024 | https://conductscience.org/library/papers/38854817 | PubMed |
| 38528198 | Clinical features of patients with hepatocellular carcinoma treated with radiofrequency ablation therapy: developing a simple score to determine the need for immune-adjuvant therapy. | Clin J Gastroenterol | 2024 | https://conductscience.org/library/papers/38528198 | PubMed |
| 38332774 | Risk Models for Predicting the Recurrence and Survival in Patients With Hepatocellular Carcinoma Undergoing Radio-Frequency Ablation. | Clin Med Insights Oncol | 2024 | https://conductscience.org/library/papers/38332774 | PubMed |
| 38326841 | Efficacy and safety of laparoscopic liver resection versus radiofrequency ablation in patients with early and small hepatocellular carcinoma: an updated meta-analysis and meta-regression of observational studies. | World J Surg Oncol | 2024 | https://conductscience.org/library/papers/38326841 | PubMed |
| 38268916 | Adjuvant immunotherapy improves recurrence-free and overall survival following surgical resection for intermediate/advanced hepatocellular carcinoma a multicenter propensity matching analysis. | Front Immunol | 2023 | https://conductscience.org/library/papers/38268916 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/22004366
GET https://conductscience.org/api/papers/v1/22004366/cited_by?page=2